Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel

TEMPLE CITY, Calif.–(BUSINESS WIRE)–Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with autosomal…